Reaction profile
The FDA adverse-event record for ineffective, neoplasia
81 FDA adverse-event reports reference ineffective, neoplasia (VeDDRA 93007). Plate codes and volume neighbourhood below; species, breeds, and drugs follow.
- #1494 of 2,481
- by report volume (all reactions)
- 81
- reports citing this reaction
- 9.9%
- death-coded share
- Dog
- most-affected species
Release-over-release change
What changed in the latest FDA data snapshot
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. INEFFECTIVE, NEOPLASIA has 45 reports now versus 45 in that prior snapshot: 0 the same number of (0.0%).
- Report change
- +0
- Death-coded reports
- +0
- Death-coded share
- +0.0 pts
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to INEFFECTIVE, NEOPLASIA changesFDA AER · VeDDRA plate
Code 93007 VOL-LOW
VOL-LOW · DEATH-PAR · MID-PACK · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL
- VOL-LOW 81 reports
- DEATH-PAR 9.9%
- MID-PACK #1494/2481
- PHOTO-FINISH Hissing
- SPECIES-DOG Dog · 43
- DRUG-LEAD Toceranib Phospha… · 37
- DESK-WIDE 20 breeds
- BOOK-FULL 8/8 fields
Nearest volume peer: Hissing (±0 reports)
Instrument codes from this reaction’s FDA CVM adverse-event extract: volume band, death-coded share, corpus rank, photo-finish peer, lead species, lead drug, breed desk, and book completeness. Not a clinical diagnosis.
Report-volume neighbourhood around INEFFECTIVE, NEOPLASIA
Highest and lowest poles plus nearest volume peers, not a full 2,500-reaction corpus board reprint.
What the FDA AER plate says about INEFFECTIVE, NEOPLASIA
Signature read: 8 death-coded reports is the most distinctive absolute-outcome stamp on INEFFECTIVE, NEOPLASIA. Report volume sits in the middle third of the reaction corpus. 8 of 81 reports were death-coded (9.9% of named reports, not a population mortality rate). Nearest volume peer: Hissing (±0 reports). Lead species Dog (43). Lead co-reported drug Toceranib Phosphate (37).
Read these counts as reporting volume, not risk: per our methodology, Lead co-reported drug Toceranib Phosphate appears in filings alongside this reaction; that is association, not causation. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.
Species Most Affected
Breeds Most Affected
Associated Drugs
Nationwide reactions with similar profiles
Two openFDA-derived peer sets for INEFFECTIVE, NEOPLASIA, both floored at ≥50 reports so the neighborhoods stay in the advertised mass (the volume chart above is the unfloored photo-finish strip).
Similar report volume
Nearest other reactions by FDA report count (81 here).
Similar death-coded share
Nearest other reactions by death-coded share (9.9% here), distinct from the volume row.
What to do with this reaction
- Compare INEFFECTIVE, NEOPLASIA's report profile against similar reactions nationwide. See similar reactions
- Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
- Browse the full reaction directory to compare report counts across reaction types. All reactions
A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →